Last updated: 2026-09-06 12:11:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Kamada Ltd (KMDA) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $8.53, with a market capitalization of $484.63M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.50 to $9.35. This page covers its latest market performance, valuation, price trends and company information.
$484.63M | |
$8.32 | |
$17.95 | |
$3.02 | |
$8.27 | |
154.82K | |
-- | |
-- | |
$9.35 | |
$6.50 | |
-- | |
-- |
Kamada Ltd (KMDA) last closed at $8.27 as of 2026-09-04 23:31:00, unchanged from the previous close of $8.27.
During the latest regular trading session, KMDA traded between $3.02 and $17.95, with a volume of 154.82K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Kamada Ltd (KMDA) moved from $8.17 to $8.53, representing a gain of 4.41% ($0.36).
The stock traded between $8.20 and $8.59 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 130.16 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 71.2%
KMDA is currently trading at $8.53, placing it 71.2% of the way from its 52-week low of $6.50 to its 52-week high of $9.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
| Employees | 462 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kamada Ltd (KMDA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.